Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Rohto Pharmaceutical Co's Revenue for the
three
months ended in Mar. 2026 was $571 Mil. Rohto Pharmaceutical Co's average Accounts Receivable for the
three
months ended in Mar. 2026 was $339 Mil.
Hence, Rohto Pharmaceutical Co's Receivables Turnover for the
three
months ended in Mar. 2026 was 1.69.
Rohto Pharmaceutical Co (OTCPK:RPHCF) Receivables Turnover Explanation
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Rohto Pharmaceutical Co Receivables Turnover Related Terms
Rohto Pharmaceutical Co Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Rohto Pharmaceutical Co's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Rohto Pharmaceutical Co Receivables Turnover Chart
RPHCF vs PG, CL, KVUE: Receivables Turnover Comparison
For the Household & Personal Products subindustry, Rohto Pharmaceutical Co's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Rohto Pharmaceutical Co Receivables Turnover vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, Rohto Pharmaceutical Co's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Rohto Pharmaceutical Co's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Rohto Pharmaceutical Co (RPHCF) has a Receivables Turnover of 1.69 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Rohto Pharmaceutical Co and its competitors. According to the industry distribution chart, Rohto Pharmaceutical Co ranks #1303 out of 1943 companies in the Consumer Packaged Goods industry, placing it in the top 67.1%.
Is Rohto Pharmaceutical Co's Receivables Turnover too high?
Rohto Pharmaceutical Co's current Receivables Turnover is 1.69. The Consumer Packaged Goods industry median Receivables Turnover is 9.33. Rohto Pharmaceutical Co's value of 1.69 is 81.9% below this industry median. Based on the distribution chart, Rohto Pharmaceutical Co ranks #1303 out of 1943 companies in the Consumer Packaged Goods industry, which is below the industry midpoint. Overall, Rohto Pharmaceutical Co has a GF Score™ of 89/100, reflecting its overall financial health beyond just this single metric.
How does Rohto Pharmaceutical Co's Receivables Turnover compare to PG and CL?
According to the Consumer Packaged Goods industry distribution chart, Rohto Pharmaceutical Co ranks #1303 out of 1943 companies for Receivables Turnover. This places Rohto Pharmaceutical Co in the lower half of its industry. The industry median Receivables Turnover is 9.33. Rohto Pharmaceutical Co's value of 1.69 is 81.9% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Consumer Packaged Goods company?
The median Receivables Turnover among Consumer Packaged Goods companies is 9.33, based on 1,943 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Rohto Pharmaceutical Co's current Receivables Turnover of 1.69 is 81.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Rohto Pharmaceutical Co and its competitors. For the Consumer Packaged Goods industry, the median Receivables Turnover is 9.33 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Rohto Pharmaceutical Co's current Receivables Turnover is 1.69. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rohto Pharmaceutical Co stock overvalued right now?
Rohto Pharmaceutical Co (RPHCF) has a current Receivables Turnover of 1.69. The stock's GF Value™ is $21.04, compared to a current price of $15.00 — trading 28.7% below its estimated fair value. The current Receivables Turnover is 1.69 and 81.9% below the Consumer Packaged Goods industry median of 9.33. Rohto Pharmaceutical Co's overall GF Score™ is 89/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Rohto Pharmaceutical Co (RPHCF), the current Receivables Turnover is 1.69 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Rohto Pharmaceutical Co (RPHCF) Overvalued in 2026?
Based on GuruFocus' analysis, Rohto Pharmaceutical Co stock appears to be undervalued.
The current stock price of $15.00 is trading 28.7% below its estimated GF Value™ of $21.04.
Key valuation signals for RPHCF:
Receivables Turnover: 1.69
GF Value™: $21.04 vs. price of $15.00 (28.7% below fair value)
Industry Position: 81.9% below the Consumer Packaged Goods median (#1303 of 1943)
No single metric tells the full story. See the RPHCF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Rohto Pharmaceutical Co Ltd is a Japan-based company mainly engaged in the manufacture and sale of health and beauty care products. The company operates through four reportable segments: Japan, America, Europe, and Asia. Each segment manufactures and sells products related to eye care (such as eye drops and eyewash), skin care (including dermatological medications, lip balm, sunscreen, and functional cosmetics), oral medication (such as gastrointestinal and herbal medicines, and supplements), and other products such as in-vitro diagnostic reagents. It generates the majority of its revenue from Japan.
89GF Score
Get the complete analysis for RPHCF
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RPHCF has been successfully added to your 
